Back to results
US 10,501,717 B2Granted
Method and apparatus for isolating invasive and metastatic cells for evaluating therapeutics and prediction of metastatic capacity
AssigneezPredicta, Inc.
InventorsJulia Kirshner, Mukti Rajen Parikh
Life of this patent
Estimating the term…
Abstract
Embodiments provide methods to produce an assembly that mimics in vitro the human microenvironment of a primary tumor site, a secondary distant organ, and circulation. Methods and apparatuses that provide a platform for the isolation of primary tumor, invasive, and metastatic cells to be used for evaluation of therapeutic efficacy and diagnostics as applied to metastatic cancers are also provided.
Claims20
A method of identifying an anticancer or anti-hyperproliferative (anti-HPP) therapeutic comprising:
- a) adding a potential anticancer or anti-HPP therapeutic to a first component of a cell culture assembly comprising (i) the first component comprising a primary site growth medium derived from a vertebrate overlaid on a primary site growth matrix, (ii) a second component comprising a biological matrix mimetic, and (iii) a dynamic fluid component comprising a secondary site growth medium,
- wherein the dynamic fluid component is in fluid contact with the primary site growth matrix and the biological matrix mimetic, allowing cells to migrate from the primary site growth matrix through the dynamic fluid component to the biological matrix mimetic,
- wherein the secondary site growth medium has a higher serum concentration than the primary site growth medium, and
- wherein the primary site growth matrix in the first component comprises a detectable amount of metastatic cancer cells or HPP cells,
- b) allowing the metastatic cancer cells or HPP cells to migrate from the primary site growth matrix of the first component to the biological matrix mimetic of the second component,
- c) detecting the amount of metastatic cancer cells or HPP cells present in the biological matrix mimetic of the second component following the migration, and
- d) identifying the potential anticancer or anti-HPP therapeutic as an anticancer or anti-HPP therapeutic if the addition thereof in the first component reduces the migration as compared to when no such addition is made.
4 more elements
A method of identifying the efficacy of an anticancer or anti-hyperproliferative (anti-HPP) therapeutic comprising:
- a) adding an anticancer or anti-HPP therapeutic to a first component of a cell culture assembly comprising (i) the first component comprising a primary site growth medium derived from a vertebrate overlaid on a primary site growth matrix, (ii) a second component comprising a biological matrix mimetic, and (iii) a dynamic fluid component comprising a secondary site growth medium,
- wherein the dynamic fluid component is in fluid contact with the primary site growth matrix and the biological matrix mimetic, allowing cells to migrate from the primary site growth matrix through the dynamic fluid component to the biological matrix mimetic,
- wherein the secondary site growth medium has a higher serum concentration than the primary site growth medium, and
- wherein the primary site growth matrix in the first component comprises a detectable amount of metastatic cancer cells or HPP cells,
- b) allowing the metastatic cancer cells or HPP cells to migrate from the primary site growth matrix of the first component to the biological matrix mimetic of the second component,
- c) detecting the amount of metastatic cancer cells or HPP cells present in the biological matrix mimetic of the second component following the migration, and
- d) identifying the efficacy of the anticancer or anti-HPP therapeutic based on the therapeutics' impact on the migration as compared to a control.
4 more elements
Dependencies are inferred from the claim text.